Cancer
From the earliest days of President Nixon's declaration of war on cancer—when nearly all patients died soon after diagnosis—Bristol-Myers Squibb has been fighting on the front lines. Since the 1970s, we've been at the leading edge of cancer research and treatment.
Today, with early detection and more powerful medications, cancer is increasingly understood to be something patients live with, not die from. Bristol-Myers Squibb remains at the forefront of research and development with its next generation of innovative targeted cancer medications in development. We intend to offer patients a wide range of options to fight cancer: traditional cell-killing chemotherapeutic agents, targeted biologics, signal transduction inhibitors that prevent tumor growth and immunomodulators that use the body's own immune system to fight cancer.
The American Cancer Society estimates that more than 1.4 million new cases of cancer were expected to be diagnosed in 2008, and predicts about 565,650 deaths. Recognizing this, Bristol-Myers Squibb continues to invest extraordinary resources behind a number of experimental compounds in development to address unmet needs in many types of cancer.